Establishing The Capacity For H5N1 Challenge Of Ferrets Within Australia &optimizing Pandemic Vaccines In This Model
Funder
National Health and Medical Research Council
Funding Amount
$405,513.00
Summary
Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to in ....Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to institute widespread vaccination of the Australian population. It is not possible to test the vaccines in people for their effectiveness against avian influenza infection prior to a disease outbreak, so an animal model for the disease will be used to assist in optimizing the formulation of flu vaccines and in testing their efficacy in preventing infection or reducing the severity of disease. Ferrets are natural hosts for flu viruses, have similar responses to vaccination as people, and develop a similar disease to humans when infected with influenza. These animals will be used to assist vaccine manufacturers in providing the best type of vaccine for protection of Australians in the face of a global flu pandemic.Read moreRead less
Determination Of The Efficacy And Resistance Profile Of A Long Acting Neuraminidase Inhibitor Against Several Avian Infl
Funder
National Health and Medical Research Council
Funding Amount
$91,350.00
Summary
Recent events have again highlighted influenza�s potential to cause a worldwide pandemic or be used as an agent of biowarfare. As of August 2005, the highly pathogenic Avian Flu sweeping through Asia has infected 112 people, killing 57. Over 150 million chickens have been slaughtered in an attempt to stop its spread, but with infection documented in migratory birds, containment may be difficult if not impossible. Experts believe that it is only a matter of time before the Avian Flu virus is capa ....Recent events have again highlighted influenza�s potential to cause a worldwide pandemic or be used as an agent of biowarfare. As of August 2005, the highly pathogenic Avian Flu sweeping through Asia has infected 112 people, killing 57. Over 150 million chickens have been slaughtered in an attempt to stop its spread, but with infection documented in migratory birds, containment may be difficult if not impossible. Experts believe that it is only a matter of time before the Avian Flu virus is capable of human to human transmission which could result in the deaths of hundreds of thousands of people worldwide. Should a pandemic arise, either through purposely-engineered or natural processes such as avian influenza, effective vaccines are unlikely to be available for at least 3-6 months. In such an event, treatment of infection and prevention of spread through post-exposure prophylaxis would be optimal, while pre-exposure prophylaxis would be most suited to key personnel such as army, medical and emergency-response staff. Biota is a world leading antiviral drug discovery company based in Melbourne, Australia with key expertise in viral respiratory diseases, particularly influenza. Biota developed the first in class neuraminidase inhibitors (NAI) drug, zanamivir (Relenza) and through a partnership with Glaxo Smith Kline (GSK) brought it to market. Biota also developed the FluOIA� for the rapid detection of Influenza A and B. Work has been underway at Biota for some time to develop a new generation of influenza drugs designed to be more active and longer acting than the first generation products. These long acting neuraminidase inhibitors (LANI) have the benefit of less frequent administration and a lower treatment dose making them an ideal choice for stockpiling. The proposed project aims to test the antiviral activity of LANI compound against the H5N1 influenza. The results of which could assist in a decision to fast track the clinical development of the compound with the aim of adding to the national stock pile of antivirals, thus helping Australia to prevent, prepare for and respond to a potential avian influenza-induced pandemic.Read moreRead less
Detection and viability of waterborne pathogens using a gut-on-chip. This project aims to resolve a significant problem for water utilities. Microbial pathogens Cryptosporidium, norovirus and adenovirus are the main public health concern for drinking water in developed nations. Water monitoring is limited by the lack of fast, reliable detection methods and viability assays for these pathogens. This project will use a novel gut-on-a-chip to develop for the first time rapid infectivity assays for ....Detection and viability of waterborne pathogens using a gut-on-chip. This project aims to resolve a significant problem for water utilities. Microbial pathogens Cryptosporidium, norovirus and adenovirus are the main public health concern for drinking water in developed nations. Water monitoring is limited by the lack of fast, reliable detection methods and viability assays for these pathogens. This project will use a novel gut-on-a-chip to develop for the first time rapid infectivity assays for Cryptosporidium, norovirus and adenovirus. Significant benefits include improved diagnostics and water disinfection assays, improved water treatment and reduced costs with global impact.Read moreRead less
Maintaining fidelity in viral Ribonucleic acid (RNA) polymerases. This project will provide informed insights into the dynamics of viruses that currently impact a healthy start to life, ageing well and productively, and preventative healthcare. The analysis of viruses that cause gastroenteritis outbreaks will increase our understanding of how these viruses replicate and spread.
The Development Of A Cross-strain And Cross-subtype Pre Pandemic Influenza Vaccine Using Savine Technology
Funder
National Health and Medical Research Council
Funding Amount
$159,500.00
Summary
The flu vaccines in use today work by inducing antibodies to surface proteins. Flu causes disease every year but occasionally a new strain arises that is distincly differnet from previous strains and can cause wides spread disease and deaths worldwide. Our new approach is to increase the level of T cells that can recognise and kill flu infected cells from all flu strains.
Transport and innate immune properties of DNA in bacterial nano-sized vesicles. All types of living organisms release nano-sized membrane vesicles or “blebs” which they use for intercellular communication and transport of molecules. This project will determine how bacteria package DNA within these vesicles, how this DNA is transported into host cells and how it triggers immune responses in these cells.
Using Metagenomics To Determine The Causative Agent(s) Of Tick-Borne Disease In Australia
Funder
National Health and Medical Research Council
Funding Amount
$639,428.00
Summary
Tick-borne disease has emerged as a topical and controversial public health problem in Australia. We will employ state-of-the-art techniques in metagenomics to determine what microbial species (bacteria, viruses and eukaryotes) circulate in Australian ticks and whether these or different microbes are also present in humans diagnosed with tick-borne disease. The data generated will provide key information on whether tick-borne disease has a microbiological cause and, if so, the microbes involved.
Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucle ....Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucleotides (RNA or DNA) for their ability to bind target proteins. This procedure will be developed by UNSW in collaboration with the biotech company BTF Plc., Ltd., to be used in two applications. The first is the research interest of UNSW and involves the development of aptamers against hepatitis C virus. The second lies within the interests of BTF and will involve the development of aptamers against the water borne pathogen Cryptosporidium parvum.Read moreRead less
Production and application of novel diagnostic and therapeutic reagents using transgenic mice. The project will be a collaboration between the University of Queensland and PanBio Ltd. We intend to use humanized transgenic mice to produce fully human monoclonal antibodies. Fully human antibodies have great advantages over murine antibodies as diagnostics and therapeutics. These reagents will be used to 1)replace human sera , 2)replace antigens from infectious organisms in a range of diagnostic ....Production and application of novel diagnostic and therapeutic reagents using transgenic mice. The project will be a collaboration between the University of Queensland and PanBio Ltd. We intend to use humanized transgenic mice to produce fully human monoclonal antibodies. Fully human antibodies have great advantages over murine antibodies as diagnostics and therapeutics. These reagents will be used to 1)replace human sera , 2)replace antigens from infectious organisms in a range of diagnostic kits for animal and human infectious disease and 3) as therapeutic leads and 4)to discover vaccine leads. The project will allow production of diagnostic kits where this was previously not feasible or not economically viable (eg. uncommon and/or dangerous animal or human diseases) and will lead to development of novel infectious disease diagnostics and therapeutics.Read moreRead less
Characterization of metabolic networks in a microbial pathogen. New methods are needed to understand complex cellular processes such as metabolism. This proposal will support the development of methods in metabolite profiling and flux analysis that provide a global view of metabolic networks in cells and complement other profiling approaches, such as proteomics and transcriptomics. The development of these approaches (collectively termed Systems Biology) is essential for maintaining Australia sc ....Characterization of metabolic networks in a microbial pathogen. New methods are needed to understand complex cellular processes such as metabolism. This proposal will support the development of methods in metabolite profiling and flux analysis that provide a global view of metabolic networks in cells and complement other profiling approaches, such as proteomics and transcriptomics. The development of these approaches (collectively termed Systems Biology) is essential for maintaining Australia science at the forefront of international efforts (National Research Priority 3; Breakthrough science). This project will also directly contribute to our understanding of metabolism of an important human pathogen and provide training to young Australian scientists.Read moreRead less